Beáta Gasztonyi

Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort

K Gecse, Barbara D. Lovász, Klaudia Farkas et al. · Journal of Crohn s and Colitis · 2015 · 182 citations · Full text

Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease

László Kiss, Tamás Szamosi, Tamás Molnár et al. · Alimentary Pharmacology & Therapeutics · 2011 · 159 citations · Full text

Similarities in Serum Acylcarnitine Patterns in Type 1 and Type 2 Diabetes Mellitus and in Metabolic Syndrome

Judit Bene, M Márton, Márton Mohás et al. · Annals of Nutrition and Metabolism · 2012 · 55 citations

Prediction of Short- and Medium-term Efficacy of Biosimilar Infliximab Therapy. Do Trough Levels and Antidrug Antibody Levels or Clinical And Biochemical Markers Play the More Important Role?

Lóránt Gönczi, Zsuzsanna Végh, Petra A. Golovics et al. · Journal of Crohn s and Colitis · 2016 · 48 citations · Full text

Haplotype analysis of the apolipoprotein A5 gene in patients with the metabolic syndrome

Péter Kisfali, Márton Mohás, Anita Maász et al. · Nutrition Metabolism and Cardiovascular Diseases · 2009 · 36 citations

Obesity, Metabolic Syndrome, Metabolic Disorder +13